Curcumol Induces Apoptosis in SPC-A-1 Human Lung Adenocarcinoma Cells and Displays Anti-neoplastic Effects in Tumor Bearing Mice

Qi-Ling Tang1,5&, Ji-Quan Guo2&, Qi-You Wang3&, Hai-Shu Lin4, Zhou-Ping Yang5, Tong Peng1, Xue-Diao Pan5, Bing Liu5, Su-Jun Wang5, Lin-Quan Zang5*

Abstract

Curcumol is a sesquiterpene originally isolated from curcuma rhizomes, a component of herbal remedies commonly used in oriental medicine. Its beneficial pharmacological activities have attract significant interest recently. In this study, anti-cancer activity of curcumol was examined with both in vitro and in vivo models. It was found that curcumol exhibited time- and concentration-dependent anti-proliferative effects in SPC-A-1 human lung adenocarcinoma cells with cell cycle arrest in the G0/G1 phase while apoptosis-induction was also confirmed with flow cytometry and morphological analyses. Interestingly, curcumol did not display growth inhibition in MRC-5 human embryonic lung fibroblasts, suggesting the anti-proliferative effects of curcumol were specific to cancer cells. Anti-neoplastic effects of curcumol were also confirmed in tumor bearing mice. Curcumol (60 mg/kg daily) significantly reduced tumor size without causing notable toxicity. In conclusion, curcumol appears a favorable anti-cancer candidate for further development.

Keywords: Curcumol - anti-proliferation - apoptosis - lung adenocarcinoma - tumor bearing mice

Introduction

Curcuma rhizomes are herbal remedies commonly used in oriental medicine such as Ayurveda and traditional Chinese medicine (Shishodia et al., 2005; Xia et al., 2005). During the past twenty years, curcumin, one of the key active substances of curcuma rhizomes attracted great interests in biomedical research (Shishodia et al., 2005; Anand et al., 2007). So far, thousands of research papers have been published with curcumin. The research interests have been extended to other active substances of curcuma rhizomes recently.

Curcumol, a sesquiterpene is another active substance of curcuma rhizomes (Carey et al., 2013; Chen et al., 2014). Similar to curcumin, curcumol also displayed a variety of beneficial pharmacological activities in pre-clinical studies, including anti-inflammation (Chen et al., 2014), anti-rheumatism (Wang et al., 2012; Wang et al., 2014; Yu et al., 2014) and anti-seizure (Ding et al., 2014) and hepato-protection (Chen et al., 2014). Moreover, the anti-neoplastic effects of curcumol have been well reported in various cell culture models (Wang et al., 2011; Zhang et al., 2011; Tian et al., 2012; Jing et al., 2013; Guo et al., 2014). However, the in vivo anti-cancer efficacy of curcumol remained unclear. To further examine the medicinal potential of curcumol, its anti-proliferative and apoptosis-inductive activities were assessed in SPC-A-1 human lung adenocarcinoma cells while the anti-cancer effects were examined in tumor bearing mice. To test whether the suppressive effects of curcumol are more specific to cancerous cells, the impact of curcumol on the growth of non-transformed cells was also attempted using MRC-5 human embryonic lung fibroblasts as a model. To the authors’ knowledge, this is the first report on the in vivo anti-neoplastic efficacy of curcumol in lung cancer model. Findings from this study will be useful to evaluate the application of curcumol as a chemotherapeutic agent.

Materials and Methods

Chemicals

Curcumol (racemate, purity≥96.7%) was obtained from the Haimen Desihang Co. Ltd. (Zhejiang, China), curcumol was dissolved in DMSO and dilute in PBS with 0.1% DMSO to incubate cells , dilute in normal saline with 1% DMSO to treat tumor bearing mice; RPMI and fetal bovine serum (FBS) were obtained from Gibco (New York, NY, USA). Methylthiazlydiphenyl-tetrazolium bromide (MTT) was purchased from Genview...
Qi-Ling Tang et al
(California, USA). Hoechst 33258 kit, Cell cycle detection kit, Annexin V/PI kit was purchased from Kaiji Co. Ltd. (Jiangsu, China).

**Instruments**
Plate reader (BIO-RAD, California, USA) was used for the MTT assays. The apoptosis were quantified with a flow cytometer (Bechman-Coulter, California, USA), and the morphological analysis of cells was obtained with an inverted fluorescence microscope (Leica, Germany).

**Animals**
The *in vivo* study was carried out with compliance to the Guide for the Care and Use of Laboratory Animals (National Academy Press, 2011). The animal handling protocol was reviewed and approved by the Institutional Animal Care and Utilization Committee (IACUC) of the Experimental Animal Center of Guangdong Pharmaceutical University (approval no. SYXK (Yue) 2012-0125). Five-week-old BALB/c nude mice were obtained from Animal Experimental Center of Guangdong Province (Experimental Animals Certificate: SCXK (Yue) 2013-0002) (Guangdong, China). The animals were maintained in specific pathogen free animal facility with a 12h/12h light-dark cycle at 22°C-24°C and 50% humidity. The animals had free access to food and water.

**Cells culture and MTT assay**
Human lung cancer cell line SPC-A-1 and human embryonic lung fibroblast cell line MRC-5 was obtained from Culture Biology of the Chinese Academy of Sciences (Shanghai, China). SPC-A-1 cells was cultured in RPMI-1640 medium while MRC-5 cells in DMEM medium, both of them was supplemented with 10% fetal bovine serum. The cells were subcultured in a humidified atmosphere with 5% CO₂ at 37°C till reaching logarithmic growth phase.

Cells were seeded in a 96-well culture plate and treated with various concentrations of curcumol once for 24, 48 and 72h, respectively. After that, MTT assay was carried out using standard protocol and optical density (OD) was measured at 570 nm by using an enzyme-labeling instrument (BIO-RAD, USA). Cell proliferation was calculated, and the experiment was repeated 3 times.

**Apoptosis assay by hoechst 33258**
The SPC-A-1 cells and MRC-5 cells in logarithmic growth phase were seeded in 24-well culture plate, and the cells were exposed to curcumol (6.25, 12.5, 25, 50, 100µM) for 48h. Then SPC-A-1 cells were stained by Hoechst 33258, and the changes in the nuclei of cells were examined and photographed by using a fluorescence microscope (Leica, Germany).

**Determination of cell apoptosis by annexin V/PI double staining**
Logarithmic growth phase of the SPCA-1 cells were seeded in 6-wells plate with density of 1×10⁵ cells/ml. After cells were treated with various concentrations (0, 6.25, 12.5, 25, 50, 100µM) of curcumol for 48h, the cells were double stained by Annexin V/PI apoptosis kit following to the instructions. Then the cell apoptosis rate was detected in a flow cytometer (Bechman-Coulter, USA).

**Determination of cell cycle by PI staining**
Logarithmic growth phase of the SPC-A-1 cells were seeded in 6-wells plate and treated with various concentrations (0, 6.25, 12.5, 25, 50, 100µM) curcumol for 48h. Then the cells were exposed in RNase (20 µg/ml), and incubated with PI (50 µg/ml). Cell cycle distribution was analyzed using flow cytometry. The ModFit 3.1 program was used to determine the percentage of cells stalled at each phase of the cell cycle.

**Antitumor activity study of curcumol in vivo**
All the mice were injected in the right flank subcutaneously with SPC-A-1 cells (2×10⁶ cells in 100 µl per site) at right forelimb armpit. When the tumors grew to approximate 4-5 mm in diameter, the tumor bearing mice were randomly allocated to 5 groups.

All the groups were observed for 13 days, and the tumor sizes were measured every two days. Tumor diameters were determined by using a Vernier caliper, Volume= (width×length)/2. The mice were sacrificed on day 13, the tumors were isolated and weighted. And the tumors tissues were collected for Hematoxylin-eosin staining.

**Pathological observation of tumor tissue by hematoxylin-eosin staining**
Each tumor of nude mice in different groups was fixed in 4% formaldehyde, dehydrated, paraffin-embedded, sectioned, and stained with Hematoxylin-eosin to observe changes in pathological cell morphology using a light microscope.

**Data analysis and statistics**
All experimental data are presented as Mean±Standard Error of the Mean (SEM). The value of 50% inhibitory concentration (IC₅₀) was calculated with GraphPad Prism 6.05 (GraphPad Software, Inc., La Jolla, CA, USA). Two-tailed independent sample t-test was carried out with GraphPad InStat version 3.10 (GraphPad Software, Inc.). A p value less than 0.05 was considered to be statistically significant.

**Results**

**Anti-proliferative activities of curcumol**
The growth-inhibitory effects of curcumol were examined in SPC-A-1 human lung adenocarcinoma cells using cisplatin (25 µM), a common chemotherapeutic agent for lung cancer as a positive control (Figure 1 (a), (b) & (c)). Clearly, curcumol displayed time- and concentration-dependent anti-proliferative activities in SPC-A-1 cells. After 72h incubation, the 50% inhibitory concentration (IC₅₀) on proliferation was found to be 32.7 µM. Cisplatin at 25 µM possessed stronger growth inhibitory effect.

To find out whether the anti-proliferative activities of curcumol are more specific to cancerous cells, the
Impact of curcumol on the growth of MRC-5 human embryonic lung fibroblasts (non-transformed cells) was also attempted (Figure 1 (d), (e) & (f)). Interestingly, curcumol did not have much growth inhibitory effect in MRC-5 and incubation with curcumol at 100 µM for 72h only led to less than 20% inhibition in comparison to the control. Clearly, the anti-proliferative activities of curcumol appeared to be more specific to cancerous cells.

**Morphological analysis of curcumol treated SPC-A-1 cells and MRC-5 cells**

The morphology of curcumol treated SPC-A-1 cells and MRC-5 cells was observed after Hoechst 33258 staining. The nuclei of SPC-A-1 cells in control group (0 µM curcumol) emitted quite homogenous blue fluorescence (Figure 2 (a)), which could be explained by an even distribution of the chromatin in the nuclei. On the other hand, for some cells treated with curcumol, nuclear condensation, which emitting bright fluorescence was observed (Figure 2 (b), (c), (d), (e) & (f)). Moreover, the cells treated with higher levels of curcumol, i.e. 25, 50 and 100 µM had higher percentage of condensation. However, apoptotic bodies did not observed in MRC-5 cells treated by curcumol (Figure 3 (a), (b), (c), (d), (e), (f)). Clearly, curcumol treatment could induce apoptosis in SPC-A-1 cells, while did not display apoptosis in MRC-5 cells.

**Curcumol Induces Apoptosis in SPC-A-1 Human Lung AC Cells and Anti-neoplastic Effects in Tumor Bearing Mice**

As curcumol displayed promising anti-neoplastic effects in in vitro studies, its in vivo anti-cancer efficacy...
was subsequently attempted in tumor bearing mice using cisplatin (1.5 mg/kg) as a positive control. Tumors were introduced through subcutaneous injection of SPC-A-1 cells (2×10^6 cells) at right forelimb armpit. Drug treatment (curcumol or cisplatin) was started when the tumors diameter were about 4-5 mm and the drug treatment last for 12 days. At the end of the experiments, the mice were sacrificed and the tumors were isolated for further examination. The in vivo anti-cancer efficacy of curcumol is shown in Figure 6.

This mouse xenograft tumor model appeared to be fairly aggressive. For the mice in vehicle group, as they were not treated with anti-cancer agent (curcumol or cisplatin), the tumors progressed rapidly and the volumes increased by a few folds within 13 days (Figure 6 (a)).

Moreover, all tumor bearing mice suffered from severe weight loss (Figure 6 (c)). As a positive control, cisplatin at the dose of 1.5 mg/kg displayed some anti-tumor effects. Although it decreased tumor volume and weight after 12 daily doses (p<0.05 vs vehicle group), it did not have protective effect in weight loss. As a chemotherapeutic agent, curcumol exhibited dose-dependent anti-cancer activities. Although the difference was statistically insignificant, the mice received low and intermediate doses (6.67 and 20 mg/kg) tended to have smaller tumors and suffered less from weight loss in comparison to the control group. When the dose of curcumol further increased to 60 mg/kg, the in vivo anti-cancer cancer efficacy (using tumor volume, tumor weight and loss in body weight as endpoints) could be confirmed by statistical test (p<0.05 vs vehicle group). Interestingly, the anti-tumor activities of curcumol appeared to fast-acting. After 4 daily doses (60 mg/kg), curcumol was able to reduced tumor volume. The disease modifying effects of curcumol (60 mg/kg) was much faster than cisplatin (1.5 mg/kg).

The pathology of the isolated tumors was also examined. The histological observations are shown in Figure 7. The tumor cells isolated from mice treated with curcumol displayed nuclear condensation, chromatatin gathered and hyperchromatic nuclei. On the other hand, the tumor cells isolated from mice treated with cisplatin displayed nuclear condensation, chromatatin gathered and hyperchromatic nuclei.
cell shrinkage, suggesting they were undergoing apoptosis. Moreover, such signs appeared to be dose-dependent.

Discussion

According to World Health Organization, lung cancer is the leading cancer killer and it leads to 1.59 million deaths annually. As more than 80% of lung cancer cases are non-small cell lung cancer (NSCLC), we tested the anti-cancer activities of curcumol in SPC-1-A cell lines, a model for non-small cell lung cancer. Since cytotoxic combination chemotherapy, the first-line treatment for stage IV NSCLC includes platinum (cisplatin or carboplatin), we used cisplatin as the positive control.

For cytotoxic chemotherapy, the clinical toxicity and tolerability are one of the key issues. Therefore, it is of great interest to identify innovative chemotherapeutic agents that displayed selective cytotoxic effects to the malignant cells. Such selective chemotherapeutic agents may have better tolerability and safety profiles. The anti-proliferative effect of curcumol appeared to be more selective to cancer cells. For example, at 100 µM, curcumol did not possess much growth suppression in MRC-5 human embryonic lung fibroblasts (non-transformed cells); however, it induced substantial apoptosis SPC-1-A cells. The selectivity of curcumol might lead to fewer side effects. Moreover, as curcuma rhizomes are commonly used as spices in cooking and curcumol is present in curcuma rhizomes at high level, the toxicity of curcumol would be limited. Such postulation was supported by pre-clinical observation in dogs (Zhang et al., 2007). Relatively low toxicity appeared to be a major advantage of curcumol and it may lead to better clinical tolerability/safety.

Pharmacokinetics plays an important role in drug development. The pre-clinical pharmacokinetics of curcumol has been attempted in dogs and rats after intravenous administration (Zhang et al., 2007; Zhao et al., 2010). Curcumol had moderate clearance in rats (~30 ml/min/kg) but relatively rapid clearance in dogs (300~400ml/min/kg). As a cancer chemotherapeutic agent, curcumol could be delivered through prolonged intravenous infusion. Therefore, a relatively rapid clearance is not a barrier to its clinical application. Moreover, its half-life was not too short (rats: ~40 min, dogs: ~2h). So, its pharmacokinetic was unlikely a barrier to its clinical application.

The anti-tumor activities of curcumol were examined in tumor-bearing mice in this study. To our knowledge, this is the first report on its in vivo anti-cancer efficacy in NSCLC model. Curcumol displayed rapid onset disease-modifying effects and such effects could be observed as early as after 4 daily treatments. The fast-acting anti-neoplastic effects appear to be another advantage of curcumol.

The remedies used in Traditional Chinese Medicine (TCM) have emerged as an important source for anti-cancer drug discovery. Various new anti-neoplastic drugs, e.g. Huachansu (water extract of Chinese toad skin) and Kanglaite (oily extract of coix seeds) have been developed and approved for the application in oncology. These TCM originated anti-cancer drugs sometimes potentiate the anti-neoplastic effects of some standard chemotherapeutic agents and therefore offer a superior clinical anti-cancer efficacy (Zhan et al., 2012; Xie et al., 2013). Currently, cytotoxic combination chemotherapy is used as the first-line treatment for stage IV NSCLC. As curcumol worked fast and might have good safety profile, it is of great interest to test curcumol in combination together with other standard chemotherapeutic agent(s) in NSCLC. Cisplatin / carboplatin plus curcumol could be the initial attempt in the future study.

In summary, curcumol exhibited time- and concentration-dependent anti-proliferative and apoptosis-inductive activities in SPC-A-1 human lung adenocarcinoma cells and displayed anti-cancer effects in tumor-bearing mice. In conclusion, as its growth-suppressive effects were more specific to cancer cells and it might have good safety profile, curcumol appears as a favorable anti-cancer candidate for further development.

Acknowledgements

This work was supported by The National High Technology Research and Development Program of China (863) (2012AA020304), and the Project of National Great New Drug Research and Development (2011zx09102-001-31).

References

mechanism of curcurmol on inducing cell growth arrest and apoptosis in jurkat cells, a model of cd4 (+) t cells. *Intern Immunopharmacology, 21*, 375-382.


